ASPRUZYO SPRINKLE
Peakranolazine
NDAORALGRANULES, EXTENDED RELEASE
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Anti-anginal
Indications (1)
Clinical Trials (5)
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis
Started Jun 2018
14 enrolled
ALS
Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)
Started Jan 2017
40 enrolled
Angina
Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents
Started Aug 2015
5 enrolled
Angina
Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries
Started Jun 2015
0Myocardial IschemiaCoronary Artery DiseaseArteriosclerosis+1 more
Ranolazine Mediated PVC Reduction in Ischemic Heart Disease
Started Dec 2014
6 enrolled
Ventricular Premature ComplexesMyocardial Ischemia
Loss of Exclusivity
LOE Date
Jan 24, 2038
144 months away
Patent Expiry
Jan 24, 2038